References
- Varettoni M, Zibellini S, Capello D, et al. Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors. Leuk Lymphoma 2013;54:2485–2489.
- Odegard VH, Schatz DG. Targeting of somatic hypermutation. Nat Rev Immunol 2006;6:573–583.
- Walsh SH, Rosenquist R. Immunoglobulin gene analysis of mature B-cell malignancies: reconsideration of cellular origin and potential antigen involvement in pathogenesis. Med Oncol 2005;22: 327–341.
- Shaheen SP, Talwalkar SS, Lin P, et al. Waldenstrom macroglobulinemia: a review of the entity and its differential diagnosis. Adv Anat Pathol 2012;19:11–27.
- Chang H, Qi C, Trieu Y, et al. Prognostic relevance of 6q deletion in Waldenstrom's macroglobulinemia: a multicenter study. Clin Lymphoma Myeloma 2009;9:36–38.
- Ghobrial IM. Are you sure this is Waldenstrom macroglobulinemia? Hematology Educ Program Am Soc Hematol 2012:586–594.
- Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 2013;121:2051–2058.
- Landgren O, Staudt L. MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med 2012;367:2255–2256; author reply 2256–2257.
- Gachard N, Parrens M, Soubeyran I, et al. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstrom macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia 2013;27:183–189.
- Braggio E, Fonseca R. Genomic abnormalities of Waldenstrom macroglobulinemia and related low-grade B-cell lymphomas. Clin Lymphoma Myeloma Leuk 2013;13:198–201.
- Fonseca R, Braggio E. The MYDas touch of next-gen sequencing. Blood 2013;121:2373–2374.